Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11 GBX | -1.35% | -10.75% | +33.50% |
Jan. 16 | E-Therapeutics shares rise on strong financial year | AN |
Dec. 27 | E-Therapeutics shares to cease trading on OTCQX | AN |
Financials (USD)
Sales 2022 | 0.48 | Sales 2023 | 0.48 | Capitalization | 93.73M |
---|---|---|---|---|---|
Net income 2022 | -8M | Net income 2023 | -8M | EV / Sales 2022 | 306,956,621 x |
Net cash position 2022 | 25.96M | Net cash position 2023 | 31.39M | EV / Sales 2023 | 131,228,741 x |
P/E ratio 2022 |
-20.3
x | P/E ratio 2023 |
-10.5
x | Employees | 34 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.56% |
1 day | -1.35% | ||
1 week | -10.75% | ||
Current month | -19.85% | ||
1 month | -16.67% | ||
3 months | +33.33% | ||
6 months | -14.40% | ||
Current year | +33.50% |
Managers | Title | Age | Since |
---|---|---|---|
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 20-01-31 |
Director of Finance/CFO | - | - | |
Alan Whitmore
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Trevor Jones
CHM | Chairman | 82 | 15-10-27 |
Director/Board Member | 68 | 20-02-10 | |
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 20-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 11 | -1.35% | 169,640 |
24-03-27 | 11.15 | -4.90% | 252,011 |
24-03-26 | 11.72 | -3.30% | 98,333 |
24-03-25 | 12.12 | -0.82% | 749,944 |
24-03-22 | 12.22 | -0.81% | 200,944 |
Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+33.50% | 81.25M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |